3rd Quarter - Report
BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.
Client
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act Priority for Pediatric Cures Act (H.R.10359)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID ADAMS | — |
| SCOTT HINKLE | — |
| AMANDA MALAKOFF | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.